Primary Wholesaler
The drug distributor a pharmacy buys most of its inventory from, usually under a contract with purchase-volume commitments and pricing tiers.
150 plain-language definitions of pharmacy reimbursement, PBM, Medicare Part D, clinical, compliance, and operations terms.
[ 150 of 150 terms ]
A federal program requiring manufacturers to sell outpatient drugs at steep discounts to eligible safety-net providers, which often dispense through contracted retail pharmacies.
A compounding pharmacy that prepares patient-specific compounded drugs under a prescription, regulated mainly by state boards of pharmacy.
A facility that compounds sterile drugs in larger quantities, with or without patient-specific prescriptions, registered with and inspected by the FDA under current good manufacturing practice.
The price a pharmacy actually pays for a drug after discounts. Many state Medicaid programs base ingredient-cost reimbursement on an estimate of AAC, often using NADAC.
Third-party validation of a pharmacy's quality and processes, such as from URAC, ACHC, or the Joint Commission. Often required for specialty and payer network access.
Angiotensin-converting enzyme inhibitor; a drug class used mainly for high blood pressure and heart failure, such as lisinopril.
What a pharmacy pays its wholesaler or supplier for a drug, net of invoice discounts. Comparing acquisition cost to reimbursement shows the margin on each claim.
How closely a patient takes medications as prescribed. Adherence affects health outcomes and, in Medicare, plan Star Ratings.
A harmful or unintended response to a medication at a normal dose.
The average price wholesalers and certain pharmacies pay manufacturers for a drug. AMP is reported to CMS and used to calculate Medicaid drug rebates and Federal Upper Limits.
Medicare's open enrollment, October 15 to December 7 each year, when beneficiaries can switch Part D and Medicare Advantage plans for the next January.
A blood thinner that prevents or reduces blood clotting, such as apixaban or warfarin.
Laws or contract terms requiring a plan or PBM to let any pharmacy join its network if the pharmacy accepts the network's terms.
A manufacturer-reported price net of most discounts, used by Medicare to pay for most Part B drugs (generally ASP plus 6%).
A published list-price benchmark for drugs. Despite the name, it is not what pharmacies pay; contracts often reimburse brand drugs as AWP minus a percentage.
A guaranteed average discount off AWP across all brand claims in a contract period. If actual reimbursement beats the guarantee, the PBM may claw back the difference at reconciliation.
Identifiers on a prescription card that route a pharmacy claim: the BIN identifies the processor, the PCN identifies the benefit, and the group number identifies the employer or plan.
The share of a dose that reaches the bloodstream and can have an effect.
Two drug products that deliver the same active ingredient at a rate and extent of absorption without a significant difference. Bioequivalence is the basis for generic approval.
A medicine made from living cells, such as insulin, monoclonal antibodies, or vaccines. Biologics are usually more complex and costly than small-molecule drugs.
A biologic that is highly similar to an FDA-approved reference biologic with no clinically meaningful differences in safety or effectiveness.
The FDA's strongest label warning, used when a drug carries a serious or life-threatening risk.
The state agency that licenses pharmacies and pharmacists and enforces state pharmacy law.
A drug sold under a trademarked name by the company that developed it, often under patent protection.
When an employer or health plan contracts its pharmacy benefit separately from its medical benefit, often with a standalone PBM.
The final Part D coverage phase. Once a beneficiary's out-of-pocket costs reach the annual cap, they pay nothing more for covered Part D drugs that year.
A model where prescriptions are filled at a central automated facility and delivered to a pharmacy or patient, freeing store staff for patient care.
Canceling a previously submitted pharmacy claim, for example when a prescription is not picked up within the allowed return-to-stock window.
Money a PBM or plan takes back from a pharmacy after a claim is paid, for example through effective-rate reconciliation, audit recoupment, or a patient copay that exceeds the drug's reimbursed cost.
Pharmacy practice focused on direct patient care: optimizing medication use and promoting health and disease prevention.
A pharmacy that does not serve walk-in customers, such as long-term care, mail-order, or some specialty pharmacies.
The federal agency that runs Medicare, works with states on Medicaid, and publishes Part D plan, pricing, and quality data.
A patient's share of a drug's cost expressed as a percentage, such as 25%, rather than a fixed dollar copay.
A formal agreement that lets a pharmacist perform certain patient care functions, such as adjusting doses or initiating therapy, under a protocol with a prescriber. Scope varies by state.
Preparing a customized medication by combining or altering ingredients to meet a specific patient's needs, such as a different strength or dosage form.
An interactive review of all of a patient's medications by a pharmacist or other qualified provider, required as part of Part D Medication Therapy Management programs.
A drug regulated by the DEA because of its potential for abuse or dependence, classified into Schedules I through V.
A plan design in which manufacturer copay assistance does not count toward a patient's deductible or out-of-pocket maximum.
A plan design that spreads the full value of manufacturer copay assistance across the plan year, typically by raising the patient's cost share for specialty drugs.
A fixed dollar amount a patient pays for a covered prescription, such as $10 for a generic. The plan pays the rest of the agreed price to the pharmacy.
A transparent pricing model where the drug price is the acquisition cost plus a set markup and dispensing fee, rather than a discount off a list-price benchmark.
A former Part D phase where patients paid a larger share of drug costs. The Inflation Reduction Act eliminated it starting in 2025.
A code on a claim (0 to 9) that tells the payer why a brand or generic was dispensed, for example DAW 1 when the prescriber requires the brand.
How many days a dispensed quantity should last at the prescribed dose. Plans use days supply to apply refill timing and quantity limits.
The DEA order form, paper or electronic (CSOS), required to order Schedule I and II controlled substances.
A registration number the Drug Enforcement Administration assigns to prescribers and pharmacies that handle controlled substances.
The amount a patient pays for covered drugs each year before the plan starts sharing costs.
Separating PBM compensation from drug list prices and rebates, typically by paying PBMs a flat service fee. Federal law requires delinking in Medicare Part D starting in 2028.
Direct and Indirect Remuneration: price concessions PBMs historically collected from pharmacies months after a Part D claim was paid. Since January 1, 2024, pharmacy price concessions in Part D must be reflected at the point of sale.
The fee paid to a pharmacy, on top of ingredient cost, for the professional service and overhead of filling a prescription.
A change in a drug's effect when taken with another drug, which may increase side effects or reduce effectiveness.
A federal law requiring electronic, interoperable tracing of prescription drug packages through the supply chain to identify and remove counterfeit or illegitimate products.
A person enrolled in both Medicare and Medicaid. Dual eligibles receive Extra Help with Part D costs automatically.
Electronic transmission of a prescription from the prescriber to the pharmacy, typically using the NCPDP SCRIPT standard.
A contractual guarantee that a pharmacy's average reimbursement across a group of claims will equal a set discount off a benchmark such as AWP. Shortfalls or overages are settled at reconciliation.
A digital record of a patient's health information used by providers. Pharmacies increasingly exchange data with EHRs for prescriptions, immunizations, and care coordination.
Completing prior authorization requests electronically within prescriber and pharmacy systems, reducing fax and phone delays.
Electronic transmission of controlled-substance prescriptions with identity proofing and two-factor authentication. Required for Medicare Part D controlled-substance prescriptions.
The Employee Retirement Income Security Act, the federal law governing most private employer benefit plans. ERISA fiduciary duties apply to how self-funded employers manage pharmacy benefits.
A Medicare program that lowers Part D premiums, deductibles, and copays for people with limited income and resources.
The federal agency that approves drugs and biologics and regulates their safety, effectiveness, manufacturing, and labeling.
Fast Healthcare Interoperability Resources, a modern HL7 standard for exchanging healthcare data through APIs.
A plan's list of covered drugs, usually organized into tiers that set the patient's cost sharing.
A request asking a plan to cover a non-formulary drug or to lower its cost-sharing tier, usually supported by the prescriber's statement of medical need.
A cap on what Medicaid will reimburse for many multiple-source generic drugs, generally set at 175% of the weighted average AMP.
Improper payments and practices that Medicare and Medicaid programs work to prevent. Part D network pharmacies are expected to have FWA compliance programs.
A medication equivalent to a brand-name drug in active ingredient, strength, dosage form, route, and performance, typically sold at a much lower price.
Dispensing an FDA-rated therapeutically equivalent generic in place of the prescribed brand, as permitted by state law.
A guaranteed average discount off AWP across all generic claims in a contract period. Because generic AWPs vary widely, GER contracts can produce large year-end clawbacks.
A drug class used for type 2 diabetes and, for some products, weight management, such as semaglutide and tirzepatide. GLP-1s are among the highest-spend drugs in pharmacy benefits.
An organization that uses the combined buying power of its members to negotiate discounts from wholesalers and manufacturers.
The Health Insurance Portability and Accountability Act, which sets national standards for protecting patient health information and for electronic healthcare transactions.
Health Level Seven, a family of standards for exchanging clinical data between healthcare systems.
A pharmacy that holds a contract with a plan's pharmacy network and accepts the network's reimbursement terms.
A medical condition a drug is approved or used to treat.
The 2022 law that created the Medicare Drug Price Negotiation Program, redesigned the Part D benefit with an annual out-of-pocket cap, and added manufacturer inflation rebates.
The portion of a claim's reimbursement that pays for the drug itself, separate from the dispensing fee and any incentive fees.
A biosimilar the FDA has determined can be substituted for the reference product at the pharmacy without prescriber intervention, subject to state law.
How many times a pharmacy sells through its average inventory in a year. Higher turns mean less cash tied up in stock.
A drug that, by federal law, can be dispensed only with a prescription.
A pharmacy serving nursing homes and assisted living facilities, typically with unit-dose packaging, frequent delivery, and consultant pharmacist services.
A PBM- or state-set maximum amount a plan will pay for a multiple-source drug, usually generics. MAC lists are proprietary and change frequently; pharmacies can appeal MAC prices below acquisition cost.
A pharmacy's formal request that a PBM raise a MAC price that is below the pharmacy's acquisition cost. Many states set timelines and requirements for MAC appeals.
A pharmacy that dispenses and ships prescriptions, often 90-day supplies of maintenance drugs. Many large PBMs own mail-order pharmacies.
The price CMS negotiates with a manufacturer for a selected drug under the Medicare Drug Price Negotiation Program. Ten drugs took effect in 2026 and 15 more take effect in 2027.
Medicaid coverage delivered through private managed care organizations under contract with a state, which often manage the pharmacy benefit through a PBM.
Private plans that deliver Medicare Part A and Part B benefits, usually with Part D drug coverage included (MA-PD).
The IRA program under which CMS negotiates prices for selected high-spend Medicare drugs. Pharmacies are paid the negotiated price by plans and receive refunds from manufacturers for the difference.
Drugs covered under Medicare's medical benefit, mainly those administered in a clinic or by a provider, plus certain items dispensed by pharmacies such as some diabetic supplies and immunosuppressants.
Medicare's outpatient prescription drug benefit, delivered through private stand-alone drug plans (PDPs) and Medicare Advantage drug plans (MA-PDs).
A Part D option, available since 2025, that lets enrollees spread their out-of-pocket drug costs into monthly payments across the year instead of paying at the pharmacy.
The CMS system that shares negotiated-price claim data with manufacturers and can pass manufacturer refunds to pharmacies. Pharmacies enroll in the MTF to receive refunds.
Aligning a patient's refills so their maintenance medications can be picked up on a single day each month, improving adherence and pharmacy workflow.
Pharmacist services that help patients get the best results from their medications. Part D plans must offer MTM programs to eligible beneficiaries.
A CMS benchmark, updated weekly, based on surveys of what retail community pharmacies pay for drugs. Many state Medicaid programs use NADAC to set ingredient-cost reimbursement.
The National Council for Prescription Drug Programs, which develops the standards pharmacies use for claims (Telecommunication Standard) and e-prescribing (SCRIPT).
A unique 10-digit, three-segment identifier for each drug product and package in the U.S., shown in an 11-digit format on claims.
The price a Part D plan and pharmacy agree to for a drug, including any dispensing fee. It is specific to each pharmacy, plan, and drug, and drives both the pharmacy's payment and the patient's cost sharing.
A unique 10-digit identifier for healthcare providers, including pharmacies, issued through CMS and used on claims.
The HHS Office of Inspector General's list of individuals and entities barred from federal healthcare programs. Pharmacies screen staff against it.
The FDA's list of approved drug products with therapeutic equivalence evaluations, used to determine which generics can be substituted for a brand.
A drug or biologic developed to treat a rare disease or condition, which may receive special FDA incentives.
A drug that is safe and effective for use without a prescription.
The most a patient pays for covered services in a plan year. In Medicare Part D, the out-of-pocket cap is $2,100 in 2026 and $2,400 in 2027.
A PBM model in which the plan pays exactly what the pharmacy is paid, and manufacturer rebates are passed to the plan, with the PBM earning an administrative fee instead of spread.
A company that manages prescription drug benefits for health plans and employers: building pharmacy networks, processing claims, setting formularies, and negotiating rebates with manufacturers.
A review by a PBM of a pharmacy's claims and records. Findings can lead to recoupment of payments, so documentation and audit defense are important for pharmacies.
An adherence measure: the share of days in a period a patient had medication on hand. A PDC of 80% or more is commonly treated as adherent and feeds Medicare Star Ratings.
The record a Part D plan submits to CMS for each paid claim, used for payment reconciliation and program oversight.
A state database of controlled-substance prescriptions that prescribers and pharmacists check to identify misuse and unsafe combinations.
A stand-alone Medicare Part D plan that adds drug coverage to Original Medicare. The average beneficiary has 9 PDPs to choose from in 2027, down from 11.
The study of how a person's genes affect their response to drugs, used to guide drug selection and dosing.
How the body absorbs, distributes, metabolizes, and eliminates a drug over time.
The core software a pharmacy uses to process prescriptions, adjudicate claims, manage inventory, and keep patient profiles. Examples include PioneerRx, Liberty, and BestRx.
The 12-month period a plan's benefits, formulary, and pricing apply to. For Medicare Part D it runs January 1 to December 31.
A subset of a plan's network where patients pay lower cost sharing, typically in exchange for lower reimbursement to the participating pharmacies.
The drug distributor a pharmacy buys most of its inventory from, usually under a contract with purchase-volume commitments and pricing tiers.
An organization that contracts with PBMs and payers on behalf of many independent pharmacies and provides services such as reconciliation, credentialing, and audit support.
The FDA's database of licensed biologics, including biosimilars and interchangeable biosimilars.
A pharmacy's process for detecting, documenting, and preventing medication errors, often called continuous quality improvement (CQI) and required by many state boards.
A plan rule capping how much of a drug is covered over a period, such as 30 tablets per 30 days.
A payment from a drug manufacturer to a PBM or plan, usually in exchange for favorable formulary placement. Rebates are paid after the sale and generally do not flow to the pharmacy.
Matching what a pharmacy was paid against what it was owed: claims to remittances, effective-rate guarantees to actual results, and manufacturer refunds to negotiated-price claims.
An NCPDP code returned when a claim is denied, explaining why, such as a refill too soon or a prior authorization requirement.
The electronic payment explanation a pharmacy receives from a payer, detailing which claims were paid, adjusted, or recouped in each payment.
An FDA-required safety program for certain drugs with serious risks, which may limit which pharmacies can dispense them or require patient monitoring.
Reversing claims and returning unclaimed prescriptions to inventory after a set number of days, as required by most payer contracts.
A drug chosen by CMS for price negotiation under the Medicare Drug Price Negotiation Program.
An employer health plan in which the employer pays claims directly rather than buying fully insured coverage. The employer carries the financial risk and controls pharmacy benefit design.
The directions for use on a prescription, often written in abbreviations such as "1 tab PO BID". See the sig code reference for common abbreviations.
A window outside annual enrollment when a Medicare beneficiary can change plans because of a qualifying event, such as moving or losing other coverage.
A pharmacy focused on high-cost, high-touch medications for complex or rare conditions, often with patient support, limited distribution access, and payer accreditation.
A formulary tier for high-cost drugs, usually with coinsurance rather than a flat copay. In Part D, drugs above a monthly cost threshold may be placed on the specialty tier.
When a PBM charges a plan sponsor more for a drug than it pays the pharmacy and keeps the difference as revenue.
CMS's 1-to-5-star quality ratings for Medicare Advantage and Part D plans. Medication adherence measures for diabetes, cholesterol, and blood pressure drugs make pharmacies important to plan scores.
A plan rule requiring a patient to try a lower-cost or preferred drug before a more expensive one is covered.
Coverage a self-funded employer buys to protect against unusually large individual or total claims.
Drug products that are pharmaceutical equivalents and can be expected to have the same clinical effect and safety profile. The FDA publishes ratings in the Orange Book.
A formulary that groups drugs into tiers, such as preferred generic, generic, preferred brand, non-preferred, and specialty, each with different patient cost sharing.
A company that administers claims and plan operations for a self-funded employer without taking on insurance risk.
A temporary supply of a non-formulary drug that a Part D plan must cover for new enrollees or after formulary changes, giving time to switch drugs or request an exception.
A PBM that discloses its pricing, rebates, and fees to the plan sponsor, often using pass-through or cost-plus pricing.
The Part D spending that counts toward a beneficiary's annual out-of-pocket cap, including what the patient pays and certain payments made on their behalf.
The cash price a pharmacy charges the general public for a drug. Many contracts require the pharmacy to be paid the lower of the contracted rate or its U&C.
A nonprofit that sets standards for medicine quality, strength, and purity, including the compounding chapters USP <795>, <797>, and <800>.
USP standards for nonsterile compounding (<795>), sterile compounding (<797>), and handling hazardous drugs (<800>), enforced by many state boards of pharmacy.
A review of prescriptions or services to confirm they are necessary, appropriate, and cost-effective, used by plans and PBMs.
The manufacturer's list price to wholesalers, before discounts or rebates. WAC is the default basis for Medicare negotiated-price refunds to pharmacies.
Get a free 30-minute deep dive into your pharmacy operations with our team.